Page last updated: 2024-11-11

ursodoxicoltaurine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tauroursodeoxycholate : An organosulfonate oxoanion that is the conjugate base of tauroursodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

tauroursodeoxycholic acid : A bile acid taurine conjugate derived from ursoodeoxycholic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9848818
CHEMBL ID272427
CHEBI ID80774
SCHEMBL ID40764
MeSH IDM0099280

Synonyms (63)

Synonym
2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl)amino)ethanesulfonic acid
tauroursodeoxycholic acid
ursodeoxycholyltaurine
ethanesulfonic acid, 2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl)amino)-
taurine, n-(3-alpha,7-beta-dihydroxy-5-beta-cholan-24-oyl)-,
ur 906
sodium tauroursodeoxycholate, >=95%
tauroursodeoxycholate
14605-22-2
ursodoxicoltaurine
tudca
taurursodiol
ur-906
tauroursodesoxycholic acid
chebi:80774 ,
ursodeoxy cholic acid
CHEMBL272427 ,
bdbm50236230
2-((r)-4-((3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic acid
3alpha,7beta-dihydroxy-5beta-cholan-24-oic acid n-(2-sulfoethyl)amide
T1567
LMST05040015
n-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)-taurine
2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7-bis(oxidanyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-1-oxopentyl]amino]ethanesulfonic acid
A808445
2-[(4r)-4-[(1s,2s,5r,7s,9s,10r,11s,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]ethane-1-sulfonic acid
S3654
60eux8mn5x ,
unii-60eux8mn5x
who 11388
taurolite
taurursodiol [usan]
relyvrio (sodium phenylbutyrate + taurursodiol)
tuda
gtpl4746
ursodoxicoltaurine (inn)
DB08834
SCHEMBL40764
ursodoxicoltaurine [inn]
ursodoxicoltaurine [who-dd]
3.alpha.,7.beta.-dihydroxy-5.beta.-cholanoyltaurine
2-{[(3alpha,5beta,7beta)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethane-1-sulfonic acid
n-ursodeoxycholoyltaurine
2-[(3alpha,7beta-dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonic acid
3alpha,7beta-dihydroxy-5beta-cholanoyltaurine
ethanesulfonic acid,2-[[(3a,5b,7b)-3,7-dihydroxy-24-oxocholan-24-yl]amino]-
AC-34539
2-{[(3alpha,5beta,7alpha,8alpha,14beta,17alpha)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonic acid
tauroursodeoxycholic acid;tudca
EX-A730
D11836
taurursodiol (usan)
tauroursodeoxycholic acid, sodium salt
2-((r)-4-((3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
3,7-dihydroxy-n-(2-sulfoethyl)cholan-24-imidic acid
DTXSID80932754
Q7688907
HY-19696
CS-0016289
HMS3885C19
CCG-269687
AKOS040746761

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" When ursodeoxycholate (final concentration, 30 mumol/L or 100 mumol/L) was added to mitochondrial incubations containing chenodeoxycholate or lithocholate, the toxic effects of lipophilic bile acids on mitochondrial oxidative metabolism were partially reversed."( Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria.
Fischer, S; Krähenbühl, S; Reichen, J; Talos, C, 1994
)
0.29
" The cellular mechanism(s) of toxicity and nature of the AbetaE22Q toxic assemblies are not completely understood."( Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells.
Castro, RE; Fossati, S; Ghiso, J; Meyerson, J; Nunes, AF; Ramalho, RM; Rodrigues, CM; Rostagno, A; Viana, RJ, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36
" Based on the analysis using principle components analysis (PCA), toxic groups could be distinguished from their control groups, which suggested that the variance of the contents of bile acids could evaluate hepatotoxicity caused by ET and DB."( [Evaluation on hepatotoxicity caused by Dioscorea bulbifera based on analysis of bile acids].
Chen, CC; Hu, ZB; Ji, LL; Wang, JM; Wang, ZT; Xu, Y; Yang, L, 2011
)
0.37
" It is suggested that TUDCA therapy is safe and appears to be more effective than UDCA in the treatment of liver cirrhosis, particularly in the improvement of the biochemical expression."( Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial.
Hou, XH; Li, AH; Li, L; Pan, XL; Xu, KS; Yang, L; Ye, J; Zhao, L, 2013
)
0.39
" Supplementation with UDCA in the absence of Bsep caused adverse effects in abcb11-/- mice."( Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Forrest, D; Hagey, LR; Hofmann, AF; Ling, V; Liu, L; Sheps, JA; Wang, R, 2013
)
0.39
"2,4-Dichlorophenol (2,4-DCP) is an environmental pollutant exhibiting a wide spectrum of toxic effects."( Endoplasmic reticulum stress is involved in 2,4-dichlorophenol-induced hepatotoxicity.
Chen, P; Fu, J; Zhang, X; Zhang, Y, 2016
)
0.43
" Both drugs were well tolerated, with comparable adverse event rates between the 2 groups."( A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.
Chen, C; Chen, G; Chen, M; Cheng, L; Duan, L; Fu, X; Gao, Z; Han, Y; Hu, H; Jia, J; Ma, H; Miao, X; Ning, Q; Sheng, J; Shi, G; Tang, H; Wang, G; Wang, J; Wei, L; Wu, S; Xie, Q; Xie, W; Xu, J; Yan, H; Yao, C; Zeng, M; Zhu, Y, 2016
)
0.43
"TUDCA is safe and as efficacious as UDCA for the treatment of PBC, and may be better to relieve symptoms than UDCA."( A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.
Chen, C; Chen, G; Chen, M; Cheng, L; Duan, L; Fu, X; Gao, Z; Han, Y; Hu, H; Jia, J; Ma, H; Miao, X; Ning, Q; Sheng, J; Shi, G; Tang, H; Wang, G; Wang, J; Wei, L; Wu, S; Xie, Q; Xie, W; Xu, J; Yan, H; Yao, C; Zeng, M; Zhu, Y, 2016
)
0.43
"It has been well established that HMG-CoA reductase inhibitors (statins) cause adverse side effects in skeletal muscle ranging from mild to fatal myotoxicity upon dose, drug interaction, and exercise."( C/EBP homologous protein deficiency inhibits statin-induced myotoxicity.
Han, JH; Kim, S; Kim, SY; Kim, WH; Lee, CH; Lim, JH; Park, KM; Shin, DS; Woo, CH, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
"Cyclosporin A (CsA) exhibits poor bioavailability after oral administration of Sandimmune, with wide intra- and interindividual variations."( Effects of tauroursodeoxycholate solutions on cyclosporin A bioavailability in rats.
Balandraud-Pieri, N; Bertault-Pérès, P; Caroli-Bosc, FX; Durand, A; Montet, AM; Montet, JC; Queneau, PE, 1997
)
0.3
" Exercise induces AMPK activation and subsequent PPARδ activation, which help to reduce endoplasmic reticulum (ER) and oxidative stress, thus increasing NO bioavailability in endothelial cells and vascular tissues."( PPARδ Is Required for Exercise to Attenuate Endoplasmic Reticulum Stress and Endothelial Dysfunction in Diabetic Mice.
Cheang, WS; Chen, ZY; Huang, Y; Lau, CW; Ma, RC; Tian, XY; Wang, L; Wang, N; Wong, WT; Xu, A; Xu, J; Zhao, L, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" The livers and intestines were separately perfused and dose-response curves (0."( Hepatic uptake and intestinal absorption of bile acids in the rabbit.
Aldini, R; Cerre, C; Galletti, G; Lenzi, PL; Montagnani, M; Polimeni, C; Roda, A; Roda, E, 1994
)
0.29
" Dosage for both drugs was 10 mg/kg body weight daily."( [Tauro-ursodeoxycholic acid vs. ursodeoxycholic acid in the dissolution of biliary calculi. Results of a single blind study].
Chiandussi, L; De Micheli, AG; Gallo, V, 1993
)
0.29
"The therapeutic index of either taurocholate (TC) or tauroursodeoxycholate (TUDC) administration in the treatment of drug-induced cholestasis was evaluated in perfused rat liver using a dose-response study."( Therapeutic index of taurocholate or tauroursodeoxycholate in experimental drug-induced cholestasis.
Adinolfi, LE; Tripodi, MF; Utili, R,
)
0.13
" We performed a dose-response study on 24 patients with primary biliary cirrhosis who were randomly assigned to receive 500, 1000, or 1500 mg daily of tauroursodeoxycholic acid for six months."( Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study.
Battezzati, PM; Covini, G; Crosignani, A; Invernizzi, P; Podda, M; Setchell, KD; Zuin, M, 1996
)
0.29
" These results can be used as guidelines to assess the required daily dosage of TUDCA."( Effect of tauroursodeoxycholic acid (TUDCA) on biliary lipid composition.
Cianci, V; Liu, XT; Muraca, M; Vilei, MT,
)
0.13
" We determined that a minimum period of 15 days of treatment with a 8 mg/Kg/day dosage resulted in fibril removal."( Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models.
Cardoso, I; Martins, D; Merlini, G; Ribeiro, T; Saraiva, MJ, 2010
)
0.36
"At peak postnatal hyperbilirubinemia, j/j Gunn rat pups were dosed with sulfadimethoxine to induce bilirubin encephalopathy."( Lipid peroxidation is not the primary mechanism of bilirubin-induced neurologic dysfunction in jaundiced Gunn rat pups.
Daood, MJ; Hoyson, M; Watchko, JF, 2012
)
0.38
" Results showed that TUDCA pretreatment (once daily for 7 consecutive days) at the dosage of 200 and 400 mg/kg, but not 100 mg/kg, markedly attenuated LPS (0."( Tauroursodeoxycholic Acid Ameliorates Lipopolysaccharide-Induced Depression Like Behavior in Mice via the Inhibition of Neuroinflammation and Oxido-Nitrosative Stress.
Chen, Z; Cheng, L; Huang, C, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
anti-inflammatory agentAny compound that has anti-inflammatory effects.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
cardioprotective agentAny protective agent that is able to prevent damage to the heart.
bone density conservation agentAn agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
bile acid taurine conjugateA bile acid conjugate resulting from the formal condensation of a bile acid with the amino group of taurine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ileal sodium/bile acid cotransporterHomo sapiens (human)Ki28.00003.30006.400010.0000AID681332
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)IC50 (µMol)10.30000.00111.095810.0000AID1438627
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phospholipase A2Homo sapiens (human)Kd10.000010.000010.000010.0000AID422551
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Kd10.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Kd10.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Kd10.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Kd10.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Kd10.00000.03725.018610.0000AID422551
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)61.88330.02372.52598.9000AID1261245; AID1261246; AID324923
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Kd10.00000.03725.018610.0000AID422551
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Kd10.00000.03725.018610.0000AID422551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A4Rattus norvegicus (Norway rat)Km17.00000.24003.28416.5300AID681364
Bile salt export pumpRattus norvegicus (Norway rat)Km4.10002.20005.35007.5000AID678843
Solute carrier organic anion transporter family member 1A5Rattus norvegicus (Norway rat)Km6.60004.30006.39608.8000AID681360
Bile salt export pumpHomo sapiens (human)Km11.90004.25004.52504.8000AID680938
Sodium/bile acid cotransporterRattus norvegicus (Norway rat)Km14.00003.70005.36677.4000AID679119
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Km13.00000.01503.49967.0000AID682135
Solute carrier organic anion transporter family member 1A2Homo sapiens (human)Km19.00006.40007.42009.6000AID682037
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (74)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of interleukin-8 productionPhospholipase A2Homo sapiens (human)
positive regulation of MAP kinase activityPhospholipase A2Homo sapiens (human)
innate immune response in mucosaPhospholipase A2Homo sapiens (human)
neutrophil mediated immunityPhospholipase A2Homo sapiens (human)
fatty acid biosynthetic processPhospholipase A2Homo sapiens (human)
actin filament organizationPhospholipase A2Homo sapiens (human)
signal transductionPhospholipase A2Homo sapiens (human)
positive regulation of cell population proliferationPhospholipase A2Homo sapiens (human)
positive regulation of calcium ion transport into cytosolPhospholipase A2Homo sapiens (human)
lipid catabolic processPhospholipase A2Homo sapiens (human)
leukotriene biosynthetic processPhospholipase A2Homo sapiens (human)
antibacterial humoral responsePhospholipase A2Homo sapiens (human)
neutrophil chemotaxisPhospholipase A2Homo sapiens (human)
activation of phospholipase A2 activityPhospholipase A2Homo sapiens (human)
cellular response to insulin stimulusPhospholipase A2Homo sapiens (human)
intracellular signal transductionPhospholipase A2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPhospholipase A2Homo sapiens (human)
regulation of glucose importPhospholipase A2Homo sapiens (human)
phosphatidylcholine metabolic processPhospholipase A2Homo sapiens (human)
phosphatidylglycerol metabolic processPhospholipase A2Homo sapiens (human)
positive regulation of fibroblast proliferationPhospholipase A2Homo sapiens (human)
arachidonic acid secretionPhospholipase A2Homo sapiens (human)
positive regulation of protein secretionPhospholipase A2Homo sapiens (human)
positive regulation of immune responsePhospholipase A2Homo sapiens (human)
defense response to Gram-positive bacteriumPhospholipase A2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityPhospholipase A2Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptidePhospholipase A2Homo sapiens (human)
positive regulation of podocyte apoptotic processPhospholipase A2Homo sapiens (human)
phospholipid metabolic processPhospholipase A2Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium ion transportIleal sodium/bile acid cotransporterHomo sapiens (human)
response to bacteriumIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportIleal sodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportIleal sodium/bile acid cotransporterHomo sapiens (human)
chemotaxisEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
immune responseEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phospholipid catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of epithelial cell migrationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
vesicle-mediated transportEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
sphingolipid catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
regulation of cell migrationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phosphatidylcholine catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
cell motilityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of lamellipodium morphogenesisEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
phospholipase A2 activityPhospholipase A2Homo sapiens (human)
signaling receptor bindingPhospholipase A2Homo sapiens (human)
calcium ion bindingPhospholipase A2Homo sapiens (human)
bile acid bindingPhospholipase A2Homo sapiens (human)
calcium-dependent phospholipase A2 activityPhospholipase A2Homo sapiens (human)
phospholipid bindingPhospholipase A2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
protein bindingIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activityIleal sodium/bile acid cotransporterHomo sapiens (human)
nucleic acid bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
lysophospholipase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
scavenger receptor activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
calcium ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
zinc ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
hydrolase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
polysaccharide bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
alkylglycerophosphoethanolamine phosphodiesterase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phosphodiesterase I activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionPhospholipase A2Homo sapiens (human)
extracellular spacePhospholipase A2Homo sapiens (human)
cell surfacePhospholipase A2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
microvillusIleal sodium/bile acid cotransporterHomo sapiens (human)
apical plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
plasma membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID1324306Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as reduction in XBPs/XBPu ratio after 6 hrs2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID681360TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID422544Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.007 mol fraction relative to cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID680938TP_TRANSPORTER: uptake in membrane vesicles isolated from Bsep-expressing Sf9 cells2002Gastroenterology, Nov, Volume: 123, Issue:5
Functional expression of the canalicular bile salt export pump of human liver.
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1324305Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of XBPs mRNA levels after 6 hrs2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID681349TP_TRANSPORTER: uptake in ASBT-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID682081TP_TRANSPORTER: inhibition of DHEAS uptake (DHEAS: 5 uM, TUDC: 100 uM) in Xenopus laevis oocytes1998FEBS letters, Mar-13, Volume: 424, Issue:3
Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain.
AID1776369Inhibition of human NTCP-mediated [3H]-TCA uptake expressed in human HepG2 cells at 3.3 uM incubated for 10 mins by liquid scintillation counter analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors.
AID679567TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, TUDC: 100 uM) in Xenopus laevis oocytes1994The Journal of clinical investigation, Mar, Volume: 93, Issue:3
Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter.
AID681602TP_TRANSPORTER: uptake in Xenopus laevis oocytes1997Hepatology (Baltimore, Md.), Dec, Volume: 26, Issue:6
Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver.
AID422542Increase in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis rate of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.08 mol fraction relative to control2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID422555Antagonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to chenodeoxycholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1438627Inhibition of human ATX expressed in HEK293 Flp-In cells assessed as decrease in choline release from LPC measured every 30 secs for 90 mins by HVA based fluorescence assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators.
AID1261245Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1438629Non-competitive inhibition of human ATX expressed in HEK293 Flp-In cells assessed as decrease in LPC hydrolysis by Lineweaver-Burk plot analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators.
AID679119TP_TRANSPORTER: uptake in Ntcp-expressing CHO cells1998The American journal of physiology, 02, Volume: 274, Issue:2
Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells.
AID1776368Antiviral activity against HBV infected in human HepG2-NTCP cells assessed as reduction in HBeAg secretion at 1 to 10 uM incubated for 24 hrs followed by replacement with fresh medium and measured at day 5 post infection by ELISA2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors.
AID1776373Antiviral activity against HBV infected in human HepG2-NTCP cells assessed as reduction in HBeAg secretion measured at day 7 post infection by ELISA2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors.
AID515397Cytotoxicity against human HET-1A cells assessed as cell viability at >1 mM after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1324311Cytotoxicity against HEK293 cells assessed as reduction in cell viability by MTT assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID422551Binding affinity to human pancreatic recombinant 1B PLA2 expressed in Escherichia coli by resonance energy transfer assay in presence of trimethyl-ammonium-diphenylhexatriene2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID681890TP_TRANSPORTER: inhibition of Taurocholate uptake in the presence of Tauroursodeoxycholate at a concentration of 20uM in membrane vesicles from MRP4-expressing V79 cells2003Hepatology (Baltimore, Md.), Aug, Volume: 38, Issue:2
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
AID682082TP_TRANSPORTER: inhibition of BSP uptake (BSP: 10 uM, TUDC: 100 uM) in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID1324310Cytoprotective activity against DCA-induced apoptosis in human HuH7 cells at 1 mM co-treated with DCA measured after 24 hrs by propidium iodide/nuclear-staining based assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID1324312Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by MTT assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID678843TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells2000Gastroenterology, Feb, Volume: 118, Issue:2
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.
AID1324307Cytoprotective activity against DCA-induced cell death in human HuH7 cells assessed as increase in cell viability at 1 mM preincubated with cells followed by DCA addition measured after 24 hrs by MTT/INCELL assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID422545Increase in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis rate of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles relative to control2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1261246Agonist activity at wild type human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID1324304Cytoprotective activity against DCA-induced ER stress in human HuH7 cells assessed as inhibition of XBPs mRNA levels after 6 hrs2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID1324300Cytoprotective activity against DCA-induced ER stress in human HuH7 cells assessed as increase in XBPu mRNA levels after 6 hrs2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID682037TP_TRANSPORTER: uptake in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID1324301Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as increase in XBPu mRNA levels after 6 hrs2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID682135TP_TRANSPORTER: uptake in Oatp1-expressing CHO-03 cell1999The American journal of physiology, 04, Volume: 276, Issue:4
Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells.
AID422546Apparent inhibition of human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis rate of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID681545TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 5 uM, TUDC: 100 uM) in Ntcp-expressing COS-7 cells1994The American journal of physiology, Mar, Volume: 266, Issue:3 Pt 1
Expression and characterization of a functional rat liver Na+ bile acid cotransport system in COS-7 cells.
AID680040TP_TRANSPORTER: uptake of Tauroursodeoxycholate at 20 u M in Oatp1-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID422549Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of cholate-activated 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID422543Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.03 mol fraction relative to cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1324298Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of CHOP mRNA levels after 6 hrs2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID422554Agonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to control2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID422550Apparent inhibition of human pancreatic recombinant 1B PLA2 expressed in Escherichia coli assessed as hydrolysis rate of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles in presence of cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID680000TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, TUDC: 100 uM) in Xenopus laevis oocytes1995Gastroenterology, Oct, Volume: 109, Issue:4
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.
AID681352TP_TRANSPORTER: transepithelial transport (basal to apical) in Ntcp/Bsep double transfected MDCK cell2005American journal of physiology. Gastrointestinal and liver physiology, Jan, Volume: 288, Issue:1
Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump.
AID681332TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells1998The American journal of physiology, 01, Volume: 274, Issue:1
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
AID1324295Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of BIP/GRP78 mRNA levels after 6 hrs2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.
AID681364TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Gastroenterology, Sep, Volume: 117, Issue:3
Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver.
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID679789TP_TRANSPORTER: inhibition of Daunomycin uptake in canalicular membrane vesicles from SD rat1994Hepatology (Baltimore, Md.), Jul, Volume: 20, Issue:1 Pt 1
Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles.
AID681361TP_TRANSPORTER: uptake in Oatp3-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID1261229Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 100 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1776379Antiviral activity against HDV infected in human HepG2-NTCP cells assessed as reduction in intranuclear accumulation of HDV delta antigen at 10 uM incubated for 24 hrs followed by replacement with fresh medium and measured at day 5 post infection by DAPI 2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (670)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (4.18)18.7374
1990's118 (17.61)18.2507
2000's110 (16.42)29.6817
2010's296 (44.18)24.3611
2020's118 (17.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.72 (24.57)
Research Supply Index6.58 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index48.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials26 (3.76%)5.53%
Reviews25 (3.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other640 (92.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients [NCT03423121]Phase 1/Phase 259 participants (Actual)Interventional2018-06-19Completed
Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma [NCT03878654]Phase 111 participants (Actual)Interventional2019-01-10Terminated(stopped due to IRB protocol violations)
Pilot Study of The Effects of Tauroursodeoxycholic Acid (TUDCA) on Endothelial Function in Subjects With Type 2 Diabetes Mellitus [NCT03462940]2 participants (Actual)Interventional2018-04-02Terminated(stopped due to The study was halted due to low enrollment exacerbated by COVID-19.)
A Single Center, Twelve-month, Open-label, Prospective Study Followed by a Six-month Withdrawal Period to Evaluate the Efficacy, Tolerability, Safety and Pharmacokinetics of Doxycycline in Combination With Tauroursodeoxycholic Acid in Transthyretin Amyloi [NCT01171859]Phase 240 participants (Actual)Interventional2010-07-31Completed
Targeting Endoplasmic Reticulum Stress to Correct Vascular Insulin Resistance and Glycemic Dysregulation [NCT03331432]8 participants (Actual)Interventional2015-10-28Completed
A Phase III Randomized Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin [NCT03481972]Phase 3102 participants (Actual)Interventional2018-04-11Completed
Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study [NCT05753852]Phase 3184 participants (Anticipated)Interventional2021-10-25Recruiting
Effect of Endoplasmic Reticulum Stress on Metabolic Function [NCT00771901]101 participants (Actual)Interventional2008-02-29Completed
The Discovery of the Double Sphincter in Gallbladder [NCT01998451]Phase 4150 participants (Anticipated)Interventional2012-12-31Recruiting
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS) [NCT03800524]Phase 3337 participants (Actual)Interventional2019-02-22Active, not recruiting
Clinical Investigation of Efficacy of Tauroursodeoxycholic Acid (TUDCA) to Enhance Pancreatic Beta Cell Survival In Type 1 Diabetes by Reducing Endoplasmic Reticulum Stress [NCT02218619]Phase 220 participants (Actual)Interventional2015-08-31Active, not recruiting
A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical Trial to Investigate Safety and Efficacy of Tauroursodeoxycholic Acid Capsules in Treatment of Adult Primary Biliary Cirrhosis [NCT01857284]Phase 3216 participants (Actual)Interventional2009-09-30Completed
[NCT00004410]50 participants (Anticipated)Interventional1998-06-30Completed
The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis. [NCT04727320]Early Phase 160 participants (Anticipated)Interventional2021-03-05Not yet recruiting
[NCT00004441]39 participants (Anticipated)Interventional1997-09-30Completed
Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance [NCT01877551]27 participants (Actual)Interventional2013-09-30Completed
Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease [NCT03533257]Phase 295 participants (Actual)Interventional2018-08-27Completed
A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis [NCT00877604]Phase 234 participants (Actual)Interventional2008-06-30Completed
An 18 Month, Open Label Study of the Tolerability and Efficacy of a Combination of Doxycycline and Tauroursodeoxycholic Acid (TUDCA) in Patients With Transthyretin Amyloid Cardiomyopathy. [NCT01855360]Phase 1/Phase 240 participants (Actual)Interventional2013-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00771901 (3) [back to overview]Body Composition
NCT00771901 (3) [back to overview]Insulin Sensitivity in the Liver
NCT00771901 (3) [back to overview]VLDL-triglyceride (TG) Concentration
NCT00877604 (1) [back to overview]The Proportion of Responder Patients in the Two Treatment Groups According the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)-R Slope.
NCT01855360 (2) [back to overview]Changes in Strain Echocardiography
NCT01855360 (2) [back to overview]Number of Patients With Adverse Events
NCT01877551 (4) [back to overview]Glucose Uptake
NCT01877551 (4) [back to overview]Liver Fat
NCT01877551 (4) [back to overview]Body Composition
NCT01877551 (4) [back to overview]Liver Function Tests
NCT03423121 (7) [back to overview]Change in Microbiome Alpha-diversity Measured by Shannon Index at the End of the Study
NCT03423121 (7) [back to overview]Incidence of Treatment-related Adverse Events (AE)
NCT03423121 (7) [back to overview]Number of Participants With at Least One Treatment-related Adverse Event
NCT03423121 (7) [back to overview]Number of Total Treatment-related Adverse Events
NCT03423121 (7) [back to overview]Change in Fasting Bile Acid Levels in Plasma
NCT03423121 (7) [back to overview]Change in Flow Cytometric Assessments of Peripheral Blood Mononuclear Cells (PBMCs)
NCT03423121 (7) [back to overview]Change in Quality of Life Based on Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument

Body Composition

Fat mass (%) (NCT00771901)
Timeframe: Baseline and four weeks

,,
Interventionpercentage (Mean)
Before InterventionAfter Intervention
Placebo3939
Sodium Phenylbutyrate3739
Tauroursodeoxycholic Acid3939

[back to top]

Insulin Sensitivity in the Liver

HISI (hepatic insulin sensitivity index). HISI is the inverse of the product of endogenous glucose production and plasma insulin concentration and provides an index of how well circulating insulin controls the amount of glucose supplied by the liver. A higher number is indicative of greater insulin sensitivity. (NCT00771901)
Timeframe: Baseline and four weeks

,,
Intervention100/ (µmol/min * uIU/mL) (Mean)
Before InterventionAfter Intervention
Placebo0.0100.008
Sodium Phenylbutyrate0.0080.009
Tauroursodeoxycholic Acid0.0090.012

[back to top]

VLDL-triglyceride (TG) Concentration

(NCT00771901)
Timeframe: Baseline and four weeks

,,
Interventionmmol/l (Mean)
Before InterventionAfter Intervention
Placebo0.570.58
Sodium Phenylbutyrate0.890.97
Tauroursodeoxycholic Acid0.740.75

[back to top]

The Proportion of Responder Patients in the Two Treatment Groups According the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)-R Slope.

Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period. (NCT00877604)
Timeframe: 1 year

Interventionparticipants (Number)
TUDCA13
Placebo6

[back to top]

Changes in Strain Echocardiography

Outcome measure, namely changes in longitudinal echocardiographic strain, will be compared to previously determined changes derived from a cohort of patients with TTR cardiac amyloidosis who were not receiving specific therapy for amyloid deposition. (NCT01855360)
Timeframe: Time Frame: * (FDAAA) outcome measure is assessed every 6 months by serial echocardiography, with final measurement 18 months after enrollment, change at 12 months reported as pre-defined primary endpoint.

Interventionpercent LV shortening (Mean)
TUDCA and Doxycycline9.1

[back to top]

Number of Patients With Adverse Events

(NCT01855360)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
TUDCA and Doxycycline7

[back to top]

Glucose Uptake

We will examine the ability of insulin to cause muscle to take up insulin. Each subject will receive intravenous insulin for 6 hours to see how much sugar needs to be given intravenously to keep the blood sugar normal, a measure called glucose uptake. We will compare glucose uptake measured as the amount of 20% dextrose that is needed to keep the blood sugar at ~100mg/dl during insulin infusion before and after 30 days of treatment with drug or placebo. (NCT01877551)
Timeframe: Glucose uptake is measured at baseline and 30 days after study intervention

Interventionchange in glucose infusion rate (ml/hr) (Mean)
Tauroursodeoxycholic Acid0
Placebo8

[back to top]

Liver Fat

We will use MRI to measure the relative (%) amount of fat in each subject's liver before and after 30 days of treatment. This will allow us to determine if the drug reduces liver fat. This is calculated by subtracting the amount of fat in the liver at the beginning of the study from the amount of fat in the liver after 30 days of treatment. Subjects who have claustrophobia or are unable to undergo MRI will not have this measure performed. Due to these reasons liver MRS was only performed in 10 patients in the tauroursodeoxycholic acid group and 9 subjects in the placebo group (NCT01877551)
Timeframe: Pre-Treatment and Post 30 day-Treatment

InterventionChange in Percent liver fat (Mean)
Tauroursodeoxycholic Acid-0.3
Placebo1.2

[back to top]

Body Composition

We will measure how much fat is present in each subject before and after treatment with TUDCA or placebo. (NCT01877551)
Timeframe: Pre-Treatment and Post 30 day-Treatment

,
Interventionpercentage of body fat (Mean)
PrePost
Placebo32.631.7
Tauroursodeoxycholic Acid35.735.7

[back to top]

Liver Function Tests

We will measure liver function tests before and after the study drug to ensure that no abnormalities in liver function occurs with the drug. (NCT01877551)
Timeframe: Pre-Treatment and Post 30 day-Treatment

,
InterventionALT (IU/ml) (Mean)
ALT-PREALT-Post
Placebo2123
Tauroursodeoxycholic Acid2519

[back to top]

Change in Microbiome Alpha-diversity Measured by Shannon Index at the End of the Study

Change in Shannon index of the gut microbiota between baseline and end of study (16 weeks). Shot-gun metagenomic sequencing in first morning stool specimen was utilized to derive the microbiome composition. Higher values of the index indicate more diversity in the microbial community. The minimum value the Shannon index can take is 0 (no diversity). There is no upper limit to the index. (NCT03423121)
Timeframe: Baseline to 16 weeks

Interventionscore on a scale (Mean)
TUDCA Treatment-0.15
Placebo Oral Capsule0.06

[back to top] [back to top] [back to top] [back to top]

Change in Fasting Bile Acid Levels in Plasma

"The change of targeted bile acid levels over the course of 16 weeks (duration of the study) is reported.~Bile acid levels (ng/mL) were log transformed before analysis to approximate normal distribution. Units are log(levels) per 16 weeks. Values are derived from linear mixed-effects models." (NCT03423121)
Timeframe: Baseline to 16 weeks

,
Interventionlog(levels[ng/mL]) per 16 weeks (Mean)
Chenodeoxycholic AcidCholic AcidDeoxycholic AcidGlycochenodeoxycholic AcidGlycocholic AcidGlycodeoxycholic AcidGlycolithocholic AcidGlycoursodeoxycholic AcidLithocholic AcidTaurochenodeoxycholic AcidTaurocholic AcidTaurodeoxycholic AcidTaurolithocholic AcidTauroursodeoxycholic AcidUrsodeoxycholic Acid
Placebo Oral Capsule0.480.580.46-0.09-0.320.140.350.140.2-0.04-0.260.10.14-0.220.37
TUDCA Treatment0.44-0.40.140.3-0.020.10.92.30.750.05-0.23-0.310.152.521.89

[back to top]

Change in Flow Cytometric Assessments of Peripheral Blood Mononuclear Cells (PBMCs)

"Change in flow cytometric assessments over the course of 16 weeks (duration of the study).~Cells are expressed as ratios of their parent types. Units reported as change in the ratio per 16 weeks. Values are derived from linear mixed-effects models." (NCT03423121)
Timeframe: Baseline to 16 weeks

,
Interventionparent cell ratio per 16 weeks (Mean)
T helper memory cellsCytotoxic T memory cells
Placebo Oral Capsule3.052.61
TUDCA Treatment-1.34-1.9

[back to top]

Change in Quality of Life Based on Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument

Change in physical and mental health scores as assessed using the Multiple Sclerosis Quality of Life-54 (MSQOL-54) instrument over the course of 16 weeks (duration of the study). This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. Two summary scores - physical health and mental health - are derived from a weighted combination of scale scores. Higher scores suggest a better quality of life. Scores can range from 0 to 100. (NCT03423121)
Timeframe: Baseline to 16 weeks

,
Interventionscore on a scale (Mean)
MSQOL - Physical ComponentMSQOL - Mental Component
Placebo Oral Capsule0.014.57
TUDCA Treatment-0.15-0.44

[back to top]